.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Ovarian cancer remains the most lethal malignancy among gynecological diseases. Consequently, clinicians urgently need more precise biomarkers for early detection and management. Recent research highlights the transformative potential of ctDNA in ovarian cancer as a non-invasive tool. Unlike traditional serum markers, circulating tumor DNA (ctDNA) provides a real-time snapshot of the tumor's genetic profile. Therefore, it offers a promising avenue for improving patient outcomes through precision medicine.
The application of ctDNA in ovarian cancer spans several critical stages of patient care. In early screening, it provides higher specificity than CA-125, especially in detecting early-stage tumors. Furthermore, ctDNA plays a vital role in monitoring minimal residual disease (MRD) after primary surgery. By detecting molecular relapse months before imaging, it allows for earlier intervention. Moreover, clinicians can use ctDNA to predict treatment responses and tailor personalized therapies. This approach ensures that patients receive the most effective drugs based on their unique mutational landscape.
While the potential is enormous, several technical hurdles remain. Currently, the sensitivity for very early-stage detection is still being optimized. Additionally, there is a lack of global standardization in detection methods across laboratories. However, future research aims to integrate ctDNA with other biomarkers to enhance diagnostic accuracy. As technology improves, liquid biopsy will likely become a standard part of routine clinical practice for managing gynecological malignancies.
ctDNA offers superior sensitivity and specificity compared to CA-125. Specifically, it can detect molecular changes and recurrence much earlier than traditional protein markers or imaging.
Monitoring minimal residual disease (MRD) with ctDNA identifies patients at high risk of relapse after surgery. This allows doctors to adjust adjuvant therapy and potentially improve long-term survival rates.
Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
1. Abulajiang Y et al. The role of circulating tumor DNA in ovarian cancer. Discov Oncol. 2026 Jun 04. doi: 10.1007/s12672-026-05333-1. PMID: 42237054.
2. Martinelli C et al. Liquid biopsy in gynecological cancers: a translational framework from molecular insights to precision oncology and clinical practice. J Exp Clin Cancer Res. 2025;44(1):140. doi: 10.1186/s13046-025-03371-1.
3. Wang J et al. Value of ctDNA-based molecular residual disease (MRD) in evaluating the adjuvant therapy effect in ovarian cancer. J Clin Oncol. 2024;42(16_suppl):5525. doi: 10.1200/JCO.2024.42.16_suppl.5525.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A review of how ctDNA enhances early screening, MRD monitoring, and personalized treatment strategies in ovarian cancer compared to traditional biomarkers....
last month
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
